4//SEC Filing
Winton Matthew 4
Accession 0000950170-25-040318
CIK 0001693011other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 4:25 PM ET
Size
7.9 KB
Accession
0000950170-25-040318
Insider Transaction Report
Form 4
Transactions
- Award
Restricted Stock Units
2025-03-11+41,500→ 41,500 total→ Common Stock (41,500 underlying) - Award
Stock Option (right to buy)
2025-03-11+145,000→ 145,000 totalExercise: $1.06Exp: 2035-03-10→ Common Stock (145,000 underlying)
Footnotes (3)
- [F1]The exercise price represents the closing price of the Issuer's common stock on March 11, 2025.
- [F2]The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.
- [F3]The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028.
Documents
Issuer
Inozyme Pharma, Inc.
CIK 0001693011
Entity typeother
Related Parties
1- filerCIK 0001971400
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 4:25 PM ET
- Size
- 7.9 KB